Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study

he results are in from the primary antibody drug for COVID-19 tested in humans. the tiny Phase 2 clinical test involving 452 participants shows the drug can reduce the necessity for hospitalization in patients with mild-to-moderate COVID-19 symptoms compared to regulate patients. The drug’s manufacturer, Eli Lilly, released a press release announcing the trial results, …